4//SEC Filing
Eramo Anna 4
Accession 0001415889-25-024444
CIK 0001691082other
Filed
Sep 11, 8:00 PM ET
Accepted
Sep 12, 6:25 PM ET
Size
15.3 KB
Accession
0001415889-25-024444
Insider Transaction Report
Form 4
Eramo Anna
Chief Medical Officer
Transactions
- Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-09-10−6,275→ 0 totalExercise: $41.84Exp: 2034-06-26→ Common Stock (6,275 underlying) - Award
Employee Stock Option (Right to Buy)
2025-09-10+6,275→ 6,275 totalExercise: $15.00Exp: 2034-06-26→ Common Stock (6,275 underlying) - Award
Employee Stock Option (Right to Buy)
2025-09-10+155,812→ 155,812 totalExercise: $15.00Exp: 2035-09-09→ Common Stock (155,812 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-09-10−26,893→ 0 totalExercise: $41.84Exp: 2033-08-24→ Common Stock (26,893 underlying) - Award
Employee Stock Option (Right to Buy)
2025-09-10+26,893→ 26,893 totalExercise: $15.00Exp: 2033-08-24→ Common Stock (26,893 underlying)
Footnotes (4)
- [F1]One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
- [F2]The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.
- [F3]One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
- [F4]One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Documents
Issuer
LB PHARMACEUTICALS INC
CIK 0001691082
Entity typeother
Related Parties
1- filerCIK 0002030921
Filing Metadata
- Form type
- 4
- Filed
- Sep 11, 8:00 PM ET
- Accepted
- Sep 12, 6:25 PM ET
- Size
- 15.3 KB